Cell Therapeutics (CTIC +2.8%) moves higher today after publishing positive results from a pre-clinical study of Pixuvri in The Journal of Pharmacology and Experimental Therapeutics. The study showed that in a human cardiac tissue model treated with Pixuvri did not form reactive oxygen species or long lived hydroxymetabolites. Additionally, the drug inhibited formation of the long-lived hydroxymetabolite of doxorubicin, which suggests a low incidence of cardiotoxicity.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs